Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI) GRAFTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, today announced that the US Department of...

Novel compound for treatment of traumatic brain injury (TBI) demonstrates positive results in a preclinical study Strongest announced preclinical results of any drug candidate currently in development for TBI Significant results in neurobehavior as measured by actigraphy. GRAFTON, Mass., March 25, 2019 (GLOBE...